APC 366 tryptase inhibitor data

ARRS (South San Francisco) reported that a Phase Ib dose tolerance trial in the U.K. has shown no dose-limiting adverse effects in 30 patients enrolled.

Doses tested were 1.25, 2.5, and 5 mg, given three times daily for four days, inhaled from a nebulizer. ...